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Fructose 2,6_bisphosphate., the most potent activator of 6-phosphofructo-1-kinase, has been demonstrated 
to mediate the increase of glycolytic flux induced by mitogens human fibroblasts. In the present work the 
molecular basis of transmembrane control of fructose 2,6-bisphosphate has been investigated. Prostacyclin 
and isoprenaline, known to activate adenylate cyclase, are able to increase fructose 2,6-bisphosphate l vels, 
indicating that in human fibroblasts cyclic AMP plays a positive role in the control of the metabolite concen- 
tration, opposite to that exerted in hepatocytes. Substances known to activate protein kinase C such as 
phorbol 1Zmyristate 13-acetate, or to stimulate phosphoinositide turnover such as thrombin and bradyki- 
nin are also effective in raising fructose 2,dbisphosphate. Therefore, we conclude that cyclic AMP and pro- 
tein kinase C are likely involved in the control of fructose 2,6-bisphosphate levels in human fibroblasts. 
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1. INTRODUCTION 
We have previously observed that Fru-2,6-Pz, 
the most potent activator of PFK-1, is involved in 
the regulation of glycolysis in human fibroblasts. 
The stimulation of resting cells with mitogens is 
responsible for a marked increase in Fru-2,6-Pz 
content that mediates the increase of the glycolytic 
flux elicited by these agents [1,2]. Studies on the 
molecular basis of transmembrane control of 
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Fru-2,6-P2 levels in different cell types have pro- 
vided evidence for the involvement of well-known 
signal-transducing systems, such as that generating 
the second messenger CAMP or that leading to the 
activation of protein kinase C via phosphoinositide 
hydrolysis in the regulation of the metabolite con- 
centration. 
In this regard liver is the best characterized 
tissue. Fru-2,6-Pz has been shown to play a fun- 
damental role in the control of hepatic glycolysis 
and gluconeogenesis. It has been demonstrated 
that the hormonal effects on Fru-2,6-Pz content 
are mediated by changes in CAMP levels and con- 
sequently in CAMP-dependent protein kinase ac- 
tivity. The decrease in Fru-2,6-Pz levels by 
glucagon treatment has been explained by the 
property of CAMP-dependent protein kinase of 
phosphorylating the bifunctional enzyme 6- 
phosphofructo-2-kinase/fructose-2,6_bisphospha- 
tase responsible for the synthesis/degradation of 
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Fru-2,6-Pz, leading to the inactivation of the 
kinase and activation of the phosphatase [3]. 
On the other hand, in chicken embryo 
fibroblasts the control of Fru-2,6-P2 levels appears 
to be disengaged from CAMP and a role for pro- 
tein kinase C activation has been proposed, since 
the tumor promoter PMA and synthetic 
diacylglycerols, well known stimulators of protein 
kinase C, induce a rise of Fru-2,6-Pz in these cells 
[4]. Recently we postulated a similar role in the rise 
of Fru-2,6-Pz induced by thrombin in human 
platelets, showing that the positive effect of the 
agonist, known to activate phosphoinositide 
hydrolysis, can be mimicked by PMA and dioc- 
tanoylglycerol [5]. 
In view of these observations that indicate a 
complex and tissue-specific mechanism in the con- 
trol of Fru-2,6-Pz levels, we decided to investigate 
whether the above-mentioned membrane transduc- 
ing systems were also involved in the regulation of 
Fru-2,6-P2 in human fibroblasts. In this connec- 
tion we have evaluated the effect on fibroblast 
Fru-2,6-P2 levels of agents known either to in- 
crease fibroblast CAMP content, e.g. isoprenaline 
[6] and PC12 [7] or to activate directly protein 
kinase C such as PMA [8] or indirectly, through 
the stimulation of phosphoinositide turnover, for 
example thrombin [9] or bradykinin [lo]. 
2. MATERIALS AND METHODS 
Biochemicals and auxiliary enzymes for the 
assay of Fru-2,6-Pz were purchased from Boeh- 
ringer. Fru-2,6-Pz, ( - )-isoprenaline, DL-pro- 
pranolol, bradykinin, bovine thrombin, PMA 
were from Sigma (St. Louis, MO); prostacyclin’ 
was from Wellcome (London, England). Cyclic 
AMP assay kit was from Amersham International 
(Amersham, England). 
Methods for fibroblast cultures have been 
described elsewhere [2]. Approx. 5 x 104 cells were 
seeded in 35-mm multiwell dishes and grown at 
confluency. 24 h before the experiments cell 
cultures were shifted to a minimum essential 
medium in the absence of serum and the medium 
was further changed 1 h before the beginning of 
the experiments. The test substances were added to 
the dishes in small volumes and when the solvent 
was different from water, appropriate amounts 
were added to the controls. At various time inter- 
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Fig.1. Time course of CAMP (A) and Fru-2,6-P2 (B) 
levels in human fibroblasts timulated with 5 fig/ml 
PGI2 (A) or 1 ,uM isoprenaline (0). Control values are 
reported (0). Experimental details are described in 
section 2. 
vals cells were processed for Fru-2,6-Pz extraction, 
as described in [2]. Fru-2,6-Pz was determined ac- 
cording to Van Schaftingen et al. [ 111. For CAMP 
measurement the incubations were terminated by 
quickly removing the medium; dishes were added 
with 200 ,ul of cold 10% trichloroacetic acid in PBS 
and rapidly frozen. After thawing, medium was 
collected and treated with 1 vol. of 0.5 M tri-n- 
octylamine solution in freon [ 121. The upper phase 
was used for radioimmunoassay of CAMP. Cells 
attached to dishes were solubilized with 1 N NaOH 
for determination of protein content [ 131. 
Data reported are means * SE of triplicate 
dishes from a single representative experiment 
which was repeated at least three times. In the 
figures the absence of an SE bar indicates that it is 
within the symbol. 
3. RESULTS AND DISCUSSION 
To evaluate whether the stimulation of the 
adenylate cyclase system could affect Fru-2,6-Pz in 
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human fibroblasts, quiescent cells were stimulated 
with isoprenaline or PGIz. Both compounds are 
responsible for a marked and sustained rise in 
CAMP which declines to control values within 2 h 
(fig.lA), followed by a progressive increase in 
Fru-2,6-P2 levels (fig.lB). Analogous results were 
obtained on incubating the cells with 1 mM 
dibutyryl-cAMP in the presence of the 
phosphodiesterase inhibitor IBMX (0.1 mM) (not 
shown). The action of isoprenaline on the 
metabolite is entirely due to the interaction with 
the ,&adrenergic receptor since 4 pM propranolol, 
a P-adrenergic antagc%nist, prevents the rise in both 
CAMP and Fru-2,6-P2 (not shown). Therefore, it 
appears that CAMP plays a positive role in the con- 
trol of Fru-2,6-P2 in human fibroblasts, opposite 
to that occurring in hepatocytes where CAMP 
represents a negative signal for the metabolite [3]. 
Furthermore, human fibroblasts are regulated dif- 
ferently from chicken embryo fibroblasts where 
Fru-2,6-P2 levels are not affected by dibutyryl- 
CAMP [4]. A positive role for CAMP in the control 
of Fru-2,6-Ps levels has so far been demonstrated 
only in Succharomyces cerevisiue [14] and this is 
the first evidence that a similar role is played in a 
higher eucaryotic cell system. 
The possible involvement of protein kinase C in 
the control of fibroblast Fru-2,6-P2 levels was in- 
vestigated using PMA, a selective activator of the 
kinase in a variety of cells including fibroblasts [8]. 
The phorbol ester elicits a rise in Fru-2,6-P2 con- 
tent (fig.2B) in accordance with previous observa- 
tions in chicken embryo fibroblasts [4] and does 
not affect CAMP levels (not shown). From the 
same figure it emerges that thrombin and 
bradykinin are also effective in raising Fru-2,6-P2 
levels. The two mitogens are able to stimulate 
phosphoinositide metabolism in cultured fibro- 
blasts [9,10] and can also promote the release and 
metabolization of arachidonic acid to biologically 
active products such as prostaglandins [15;16]. 
These metabolites are responsible for the CAMP 
accumulation observed after stimulation of human 
fibroblasts with bradykinin [16]. The results in 
fig.ZA confirm that bradykinin produces an in- 
crease in CAMP levels that peak at 5 min and then 
progressively decline to control values within 1 h. 
Noteworthily, thrombin is almost equipotent to 
bradykinin in increasing CAMP, in contrast to 
previous observations on hamster fibroblasts 
where it has been found to be unable to affect 
CAMP levels [ 17). 
To ascertain whether the observed increase in 
CAMP content could mediate at least in part the ef- 
fect on Fru-2,6-P2 elicited by thrombin and 
bradykinin, analogous experiments were perform- 
Table 1 
Effect of indomethacin on CAMP and Fru-2,6-PZ levels in human fibroblasts stimulated 
with thrombin or bradykinin 
1lcM CAMP Fru-2,6-Ps 
indomethacin (pmol/mg (pmol/mg 
protein) protein) 
Time of incubation 
5 min lh 4h 
Control - so* 2 51.7 f 4.7 50.3 f 4.1 
+ 40f 3 48.5 f 5.2 52.4 f 3.9 
Thrombin, 4 U/ml 1709 f 40 85.1 + 7.5’ 112.4 it: 10.6 
+ 70* 5 59.2 f 5.8b 84.3 t 6.4 
Bradykinin, 1 PM 2751 f 52 110.3 f 9.78 190.4 f 11.6 
+ 59* 3 61.3 f 8.Sb 168.6 f 15.0 
a Significantly different from control p < 0.05 
b The effect of indomethacin was significant (p < 0.05) vs agents alone 
Statistical analysis was by Student’s t-test for paired data 
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Fig.2. Time course of CAMP (A) and Fru-2,6-Pz (B) 
levels in human fibroblasts stimulated with 100 ng/ml 
PMA (o), 4 U/ml thronibin (A) or 1 ,uM bradykinin 
(m). Control values for Fru-2,6-Pt are reported; the 
basal CAMP content was 50 pmol/mg protein. 
Experimental details are described in section 2. 
ed in the presence of indomethacin in order to pre- 
vent prostaglandin synthesis (table 1). The 
cyclooxygenase inhibitor, as reported in [ 161, com- 
pletely reduces hradykinin-stimulated CAMP for- 
mation and%sLsimilarly efficacious in preventing 
the rise in the cyclic nucleotide induced by throm- 
bin, demonstrating that prostaglandins also 
mediate the action of thrombin. Indomethacin 
significantly reduces the rise in Fru-2,6-Pz elicited 
by thrombiri and bradykinin at 1 h of incubation 
indicating that, at early times of incubation, the ef- 
fect on the metabolite is largely mediated by 
CAMP. On the other hand, the effect of the 
mitogens on Fru-2,6-Pz levels at longer times of in- 
cubation is likely due to molecular events linked to 
the activation of phosphoinositide hydrolysis in- 
duced by both the agents. This hypothesis is sup- 
ported by the observation that indomethacin does 
not impair the effectiveness of thrombin and 
bradykinin at 4 h of ,incubation and by the similar 
ability to increase Fru-2,6-Pz displayed by PMA, a 
known activator of protein kinase C. 
In summary, the levels of Fru-2,6-Pz, previously 
reported to regulate glycolysis in human 
fibroblasts [1,2], appear to be affected by changes 
in the concentration of CAMP: the rise of the cyclic 
nucleotide induced by stimulatory agonists of 
adenylate cyclase such as isoprenaline and PGI2, or 
by the analogous dibutyryl-CAMP in the presence 
of the phosphodiesterase inhibitor IBMX, or 
secondary to the activation of the arachidonic acid 
cascade caused by thrombin or bradykinin, is 
always responsible for an increase in Fru-2,6-P2 
levels. In addition, protein kinase C activation may 
also affect Fru-2,6-P2 levels in human fibroblasts, 
as indicated by the finding that PMA, a direct ac- 
tivator of protein kinase C, increases Fru-2,6-Pz 
levels; moreover, the effectiveness of thrombin 
and bradykinin at raising Fru-2,6-P2 levels at 
longer times of incubation, under experimental 
conditions preventing the rise in CAMP, may be 
ascribed to their ability to activate phos- 
phoinositide hydrolysis, further supporting this 
hypothesis. 
This is the first evidence for the involvement of 
CAMP- and protein kinase C-dependent pathways 
in the control of a specific metabolic effect in 
human fibroblasts, indicating that the two signal- 
transducing systems act in the same direction 
this particular cell type, both eliciting the rise 
Fru-2,6-Pz. 
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